Session II
Immunotherapy Combination with Conventional Cancer Therapies

Chair
Hideho Okada, MD, PhD
University of Pittsburgh Cancer Institute

11/17/2011 Workshop on Immunotherapy Combinations
Effective Combination Strategies

The vaccine effects can be boosted by concomitant or subsequent therapeutic modalities that
(a) modulates the characteristics of tumor cells, rendering them more susceptible to immune-attack
(b) kill populations of tumor cells which, in turn, serve as a booster for tumor-specific immune cells
(c) kill or inhibit regulatory immune cells (e.g. Treg) and thus boost the immune response
Laurence Zitvogel, M.D, Ph.D
(Institut Gustave Roussy)

“Unraveling Novel Pathways of Immunogenic Cell Death and Their Clinical Implications”

• Mechanisms of immunological cell death
• Immune-relevant biomarkers that may guide personalized therapeutic interventions
Larry W. Kwak, M.D, Ph.D.  
(MD Anderson Cancer Center)  

“Translational Development of Therapeutic Vaccines for Lymphoma”  

• Pioneering work in therapeutic Id vaccines in human patients with Dr. Ron Levy  
• Phase III study patient-specific hybridoma-derived Id-vaccine in follicular lymphoma patients post chemotherapy
Philip M. Arlen, M.D (NCI/NIH)

Prostate cancer vaccines in combination with

• Hormone therapy
• Radiotherapy of tumor
• Chemotherapy